NANO Nuclear Energy Inc.

NASDAQ•NNE

CEO: Mr. Jiang Yu

板块: Industrials

行业: Industrial - Machinery

上市日期: 2000-01-05

NANO Nuclear Energy Inc. operates as a microreactor technology company. The company is developing ZEUS, a solid-core battery reactor, and ODIN, a low-pressure coolant reactor. It is also developing a high-assay low-enriched uranium fabrication facility to supply fuel to the nuclear reactor industry and fuel transportation and nuclear consultation businesses. The company was founded in 2021 and is based in New York, New York.

联系方式

10 Times Square, 30th Floor, New York, NY, 10018, United States

212-634-9206

nanonuclearenergy.com

市值

$1.02B

市盈率 (TTM)

-28.1

21.6

股息率

52周最高

$60.87

52周最低

$17.26

52周范围

17%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基于 4 年期基本面

疲弱 • 2.2 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2022-2025

财务仪表盘

Q1 2026 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.13+0.00%

近4季度走势

自由现金流

-$3.99B+0.00%

近4季度走势

2026 Q1 财报亮点

核心亮点

Strong Financing Inflow Net cash from financing $381.33M USD; October 2025 private placement raised $400.00M gross USD.

R&D Spending Accelerates R&D expense $5.40M USD for three months, up 497% versus prior period's $0.90M USD spend.

Cash Position Strengthened Cash equivalents reached $577.53M USD December 31, 2025; working capital $576.43M USD.

Reactor Licensing Progress NRC approved Fuel Qualification Methodology Topical Report; targeting construction permit submission first half 2026.

关注风险

Future Funding Uncertainty Future capital needs require equity/debt financing; inability to raise funds could materially affect operations failure.

Regulatory Timeline Risks KRONOS reactor licensing timeline uncertain; NRC review timing outside management control, potentially delaying commercialization.

Operating Loss Widening Net loss $6.52M USD for quarter, nearly doubling prior period's $3.11M USD loss; cash used in operations $3.99M USD.

SEC Investigation Ongoing Received subpoena regarding two service providers; cannot predict outcome of SEC investigation initiated April 2025.

前瞻展望

KRONOS Commercialization Target Aiming for NRC construction permit submission first half 2026; initial operation projected between 2030 and 2031.

Illinois Facility Investment Plan investment over $12M USD in Illinois facility for manufacturing and R&D; expecting $6.8M USD in incentives.

Consulting Revenue Near Term Generating small consulting revenue in 2025; formal launch dependent on acquiring existing revenue-generating businesses.

ODINT Reactor Sale Considered Signed Letter of Intent for proposed sale of ODINT microreactor design to monetize investment and focus resources.

同行对比

营业收入 (TTM)

ZIM

$6.90B

-18.1%

$2.52B

-19.2%

ENOV

$2.25B

+6.7%

毛利率 (最新季度)

ENOV

60.7%

+3.2pp

EPAC

45.4%

-1.8pp

SXI

39.7%

+2.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
SXI	$3.28B	60.5	7.7%	40.1%
ZIM	$3.25B	6.8	12.1%	52.1%
ATS	$3.07B	223.3	1.1%	35.6%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月13日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据